The role of cytokines in liver failure and regeneration: Potential new molecular therapies

被引:95
作者
Galun, E [1 ]
Axelrod, JH [1 ]
机构
[1] Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2002年 / 1592卷 / 03期
基金
以色列科学基金会;
关键词
cytokine; liver; regeneration; stem cells;
D O I
10.1016/S0167-4889(02)00326-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The liver is a unique organ, and first in line, the hepatocytes encounter the potential to proliferate during cell mass loss. This phenomenon is tightly controlled and resembles in some way the embryonal co-inhabitant cell lineage of the liver, the embryonic hematopoietic system. Interestingly, both the liver and hematopoietic cell proliferation and growth are controlled by various growth factors and cytokines. IL-6 and its signaling cascade inside the cells through STAT3 are both significantly important for liver regeneration as well as for hematopoietic cell proliferation. The process of liver regeneration. is very complex and is dependent on the etiology and extent of liver damage and the genetic background. In this review we will initially describe the clinical relevant condition, portraying a number of available animal models with an emphasis on the relevance of each one to the human condition of fulminant hepatic failure (FHF). The discussion will then be focused on the role of cytokines in liver failure and regeneration, and suggest potential new therapeutic modalities for FHF. The recent findings on the role of IL-6 in liver regeneration and the activity of the designer IL-6/sIL-6R fusion protein, hyper-IL-6, in particular, suggest that this molecule could significantly enhance liver regeneration in humans, and as such could be a useful treatment for FHF in patients. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:345 / 358
页数:14
相关论文
共 144 条
[31]  
Gantner F, 1997, J PHARMACOL EXP THER, V280, P53
[32]  
GANTNER F, 1995, HEPATOLOGY, V21, P190, DOI 10.1002/hep.1840210131
[33]   Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat [J].
Gardner, CR ;
Heck, DE ;
Yang, CS ;
Thomas, PE ;
Zhang, XJ ;
DeGeorge, GL ;
Laskin, JD ;
Laskin, DL .
HEPATOLOGY, 1998, 27 (03) :748-754
[34]   Acute liver failure [J].
Gill, RQ ;
Sterling, RK .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (03) :191-198
[36]  
Guha C, 1999, CANCER RES, V59, P5871
[37]   Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: A rodent model of IL-4-induced hepatitis [J].
Guillot, C ;
Coathalem, H ;
Chetritt, J ;
David, A ;
Lowenstein, P ;
Gilbert, E ;
Tesson, L ;
van Rooijen, N ;
Cuturi, MC ;
Soulillou, JP ;
Anegon, I .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5225-5235
[38]   Lessons from genetically engineered animal models VI. Liver repopulation systems and study of pathophysiological mechanisms in animals [J].
Gupta, S ;
Rogler, CE .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1999, 277 (06) :G1097-G1102
[39]   NF-κB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-α- and Fas-mediated apoptosis [J].
Hatano, E ;
Bennett, BL ;
Manning, AM ;
Qian, T ;
Lemasters, JJ ;
Brenner, DA .
GASTROENTEROLOGY, 2001, 120 (05) :1251-1262
[40]   Hyper-IL-6 gene therapy reverses fulminant hepatic failure [J].
Hecht, N ;
Pappo, O ;
Shouval, D ;
Rose-John, S ;
Galun, E ;
Axelrod, JH .
MOLECULAR THERAPY, 2001, 3 (05) :683-687